Efficacy and tolerability of the long-acting somatostatin analog lanreotide in acromegaly. A 12-month multicenter study of 58 acromegalic patients

Pituitary

Volumn 2, Issue 4, 2000, Pages 269-276

  Chanson, Philippe ^a   Leselbaum, Anne ^b   Blumberg, Joelle ^b   Schaison, Gilbert ^a  

^a BICÊTRE HOSPITAL   (France)

^b IPSEN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; CYCLOPEPTIDE; DRUG DERIVATIVE; HUMAN GROWTH HORMONE; SOMATOMEDIN C; SOMATOSTATIN;

ACROMEGALY; ADULT; AGED; ARTICLE; BLOOD; CLINICAL TRIAL; FEMALE; FRANCE; HUMAN; MALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; TIME; UNIVERSITY HOSPITAL;

ACADEMIC MEDICAL CENTERS; ACROMEGALY; ADULT; AGED; FEMALE; FRANCE; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; SOMATOSTATIN; TIME FACTORS;

EID: 0034180271     PISSN: 1386341X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Melmed S. Acromegaly. In: Melmed S (ed). The Pituitary. Cambridge: Blackwell Science, 1995;413-442.
2. Melmed S, Ho K, Klibanski A, Reichlin S, Thorner M. Clinical review 75: Recent advances in pathogenesis, diagnosis, and management of acromegaly. J Clin Endocrinol Metab 1995;80:3395-3402.
3. Fahlbusch R, Honegger J, Buchfelder M. Surgical management of acromegaly. Endocrinol Metab Clin North Am 1992; 21:669-692.
4. Eastman RC, Gorden P, Glatstein E, Roth J. Radiation therapy of acromegaly. Endocrinol Metab Clin North Am 1992; 21:693-712.
5. Barkan AL, Halasz I, Dornfeld KJ, et al. Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly. J Clin Endocrinol Metab 1997;82:3187-3191.
6. Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N Engl J Med 1996;334:246-254.
7. Chanson P, Timsit J, Harris AG. Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumours. Clin Pharmacokinet 1993;25:375-391.
8. Gillis JC, Noble S, Goa KL. Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly. Drugs 1997;53:681-699.
9. Sassolas G, Harris AG, James-Deidier A. Long term effect of incremental doses of the somatostatin analog SMS 201-995 in 58 acromegalic patients. French SMS 201-995 approximately equal to Acromegaly Study Group. J Clin Endocrinol Metab 1990;71:391-397.
10. Vance ML, Harris AG. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group. Arch Intern Med 1991;151:1573-1578.
11. Ezzat S, Snyder PJ, Young WF, et al. Octreotide treatment of acromegaly. A randomized, multicenter study. Ann Intern Med 1992;117:711-718.
12. Newman CB, Melmed S, Snyder PJ, et al. Safety and efficacy of long-term octreotide therapy of acromegaly: Results of a multicenter trial in 103 patients-a clinical research center study. J Clin Endocrinol Metab 1995;80:2768-2775.
13. Arosio M, Macchelli S, Rossi CM, Casati G, Biella O, Faglia G. Effects of treatment with octreotide in acromegalic patients - A multicenter Italian study. Italian Multicenter Octreotide Study Group. Eur J Endocrinol 1995;133:430-439.
14. Fløgstad AK, Halse J, Bakke S, et al. Sandostatin LAR in acromegalic patients: Long-term treatment [see comments]. J Clin Endocrinol Metab 1997;82:23-28.
15. Stewart PM, Kane KF, Stewart SE, Lancranjan I, Sheppard MC. Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly. J Clin Endocrinol Metab 1995;80:3267-3272.
16. Lancranjan I, Bruns C, Grass P, et al. Sandostatin LAR: A promising therapeutic tool in the management of acromegalic patients. Metabolism 1996;45:67-71.
17. Heron I, Thomas F, Dero M, et al. Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly. J Clin Endocrinol Metab 1993;76:721-727.
18. Morange I, De Boisvilliers F, Chanson P, et al. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide. J Clin Endocrinol Metab 1994;79:145-151.
19. Johnson MR, Chowdrey HS, Thomas F, Grint C, Lightman SL. Pharmacokinetics and efficacy of the long-acting somatostatin analogue somatuline in acromegaly. Eur J Endocrinol 1994;130:229-234.
20. Marek J, Hana V, Krsek M, Justova V, Catus F, Thomas F. Long-term treatment of acromegaly with the slow-release somatostatin analogue lanreotide. Eur J Endocrinol 1994; 131:20-26.
21. Giusti M, Gussoni G, Cuttica CM, Giordano G. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: Six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group. J Clin Endocrinol Metab 1996;81:2089-2097.
22. Frohman LA. Acromegaly: What constitutes optimal therapy? [editorial]. J Clin Endocrinol Metab 1996;81:443-445.
23. Consensus statement: Benefits versus risks of medical therapy for acromegaly. Acromegaly Therapy Consensus Development Panel. Am J Med 1994;97:468-473.
24. Cancel A, Vuillermet P, Legrand A, Catus F, Thomas F, Kuhn JM. Effects of a slow-release formulation of the new somatostatin analogue lanreotide in TSH-secreting pituitary adenomas. Clin Endocrinol (Oxf) 1994;40:421-428.
25. Caron P, Cogne M, Gusthiot-Joudet B, Wakim S, Catus F, Bayard F. Intramuscular injections of slow-release lan-reotide (BIM 23014) in acromegalic patients previously treated with continuous subcutaneous infusion of octreotide (SMS 201-995). Eur J Endocrinol 1995;132:320-325.
26. al-Maskari M, Gebbie J, Kendall-Taylor P. The effect of a new slow-release, long-acting somatostatin analogue, lanreotide, in acromegaly. Clin Endocrinol (Oxf) 1996;45:415-421.
27. Caron P, Morange-Ramos I, Cogne M, Jaquet P. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. J Clin Endocrinol Metab 1997; 82:18-22.